Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Université´ D'aix-Marseille

Imcheck Therapeutics Sas

Institut Jean Paoli & Irene Calmette

Other

Agenus Inc.

Institut Jean Paoli & Irène Calmettes

Universite Aix-marseille

Nkt Therapeutics Inc.

Truneh, Alemseged

Olive, Daniel

Alemseged Truneh

Daniel Olive

Christine Pasero

Aude De Gassart

Timothy David Jones

Francis Joseph Carr

James Peter Gregson

Ramesh Kashi

Daniel Lewis Levey

Xiaoyan Mo

René Hoet

Magali Colazet

Chuanliang Liu

Kenneth P Leclair

Annie Xiaoyan Mo

Daniel L Levey

Ramesh S Kashi

Aston Chuanliang Liu

It is disclosed anti-BTN3A activating antibody fragments that specifically bind to BTN3A and activate the cytolytic function of Vγ9/Vδ2 T cells. The disclosure more specifically relates to specific anti-BTN3A binding proteins comprising such activating antibody fragments and their use in the manufacturing of novel drugs for use in treating cancer disorders, in particular cancers susceptible to be treated with activated γδ T cells.

BTN3A binding proteins and uses thereof

The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.

Anti-BTN3A antibodies and their use in treating cancer or infectious disorders

Methods of treatment to suppress an immune response are provided. The method comprises administering to a subject in need of treatment a naked blocking antibody that binds selectively iNKT cells in an amount effective to suppress the subject's iNKT cell function. Compositions comprising, an isolated, humanized antibody that binds selectively iNKT cells are also provided.

Humanized antibodies to iNKT

The present invention relates to methods and compositions for the prevention and treatment of herpes virus infections. The invention provides antigenic peptides, and pharmaceutical compositions comprising complexes of antigenic peptides and adjuvants that can activate an immune response against herpes viruses. The invention also provides methods of making the antigenic peptides and complexes of antigenic peptides and adjuvants. Methods of use of the pharmaceutical compositions are also provided.

Vaccine for treatment and prevention of herpes simplex virus infection

The present invention relates to ligands of HVEM for the treatment of hematologic malignancies, in particular Chronic lymphocytic leukaemia, and for the treatment of autoimmune diseases.

Ligands of HVEM for treating hematologic malignancies

Growing community of inventors

Sudbury, MA, United States of America

Alemseged Truneh